<DOC>
	<DOCNO>NCT01414101</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ISIS CRP Rx effect CRP pharmacodynamic measure , versus placebo , subject active rheumatoid arthritis .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacodynamic Study ISIS CRP Rx Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female ; age 18 75 year Active RA least 6 month Active disease define equal great 6 swollen joint 6 tender joint , base 28 joint count On stable dos regimen allow RA medication Currently receive least 10 mg methotrexate week . Patients unable tolerate dos great 10 mg may also eligible enrollment . Diagnosis Felty 's syndrome , psoriatic arthritis , gout , autoimmune rheumatic disease Any surgical procedure within 30 day Screening likely need joint tendon surgery surgical procedure study Intraarticular intramuscular corticosteroid within 60 day prior dose Previous treatment biologic response modify agent RA within 90 day 5 halflives , whichever great , prior screen Previous treatment rituximab time Use corticosteroid therapy equivalent average daily dose &gt; 10 mg prednisone Any Screening laboratory value allow reference range Inability comply protocol study procedures Any significant illness condition may adversely affect subject participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>